Latest Breaking News On - Embo reports - Page 1 : comparemela.com

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies Measuring the presence and performance of neutralizing antibodies is crucial in the fight against the coronavirus disease 2019 (COVID-19) pandemic. This allows us to glimpse how effective vaccines and antibody therapies are in conferring protective immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Researchers in Germany and the U.S. described 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potentially inhibit the connection of RBD with the angiotensin-converting enzyme 2 (ACE2). The study, published in the journal Embo Reports, shows the generation of biparatopic nanobodies as surrogates to monitor neutralizing immune responses in SARS-CoV-2 infected people. A competitive multiplex binding assay, called NeutrobidyPlex, enables high-throughput screening and extensive analyses of infected or vaccin

Bio shutterstockAngela betsaidab laguipoEberhard karls universityAngela betsaidaEmbo reportsHuen structure bioCoronavirus disease covid 19Ars cov 2Ngiotensin converting enzyme 2High throughput screeningImmune responseEvere acute respiratoryEvere acute respiratory syndromeSpike proteinஎபர்ஹாஎச் கர்ல்ஸ் பல்கலைக்கழகம்